Phase 2 trial of ERY001 in the patients with first line pancreatic cancer

Trial Profile

Phase 2 trial of ERY001 in the patients with first line pancreatic cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2018

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 24 Jun 2018 According to an ERYtech Pharma media release, this company sponsored, proof of concept study is expected to start in 2018, with patients enrollment to commence in the first half of 2019.
    • 13 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top